Retatrutide Evidence Guide
Retatrutide has the largest sponsor-reported Phase 3 weight-loss signal in the database and now has positive results across five Phase 3 studies. It remains unapproved, and the new results are not yet fully peer reviewed, so tirzepatide remains the evidence-backed approved choice while retatrutide is the leading late-stage candidate.
Our Take
Retatrutide has the largest sponsor-reported Phase 3 weight-loss signal in the database and now has positive results across five Phase 3 studies. It remains unapproved, and the new results are not yet fully peer reviewed, so tirzepatide remains the evidence-backed approved choice while retatrutide is the leading late-stage candidate.
- Evidence context
- Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: Clinical-trial only; TRIUMPH-1 used weekly 4mg, 9mg, and 12mg target doses after stepwise escalation
Benefits and Evidence
- Body Weight Reduction: Level B, includes human evidence - Phase 2 produced up to 24.2% weight loss at 48 weeks. Sponsor-reported Phase 3 results include 28.3% at 80 weeks in TRIUMPH-1, 20.8% in participants with type 2 diabetes and obesity in TRIUMPH-2, and 22.6% in severe obesity with established cardiovascular disease in TRIUMPH-3. These percentages should not be compared without accounting for different populations and estimands.
- Glycemic Control: Level B, includes human evidence - TRIUMPH-2 sponsor topline data reported HbA1c reductions of up to 1.6 percentage points at 80 weeks in participants with type 2 diabetes and obesity. Full peer-reviewed Phase 3 results are pending.
- Hepatic Fat Reduction: Level B, includes human evidence - Substantial reduction in liver fat content observed via imaging, attributed to the glucagon receptor agonist component driving hepatic lipid oxidation.
- Gastrointestinal Side Effects: Level B, includes human evidence - Nausea, diarrhea, and vomiting were the most common adverse events, generally mild to moderate and decreasing over time with dose titration.
Side Effects and Warnings
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Injection site reactions
- Not yet approved for clinical use - investigational only
- Risk of gastrointestinal adverse events, especially during dose escalation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 4 mg escalating to 12 mg - Once weekly - Dose titration over several weeks recommended to minimize gastrointestinal side effects. Highest efficacy observed at 12 mg weekly.
- <strong>Subcutaneous injection</strong> - 0.5 mg starting dose - Once weekly - Phase 2 trial starting dose, escalated every 4 weeks to target maintenance dose.
Mechanism of Action
Retatrutide functions as a triple incretin receptor agonist, simultaneously engaging three key metabolic hormone receptors: GLP-1, GIP, and glucagon. This tri-agonist approach represents a significant advancement beyond single and dual agonist therapies. At the GLP-1 receptor, retatrutide enhances glucose-dependent insulin secretion, suppresses glucagon release during hyperglycemia, and slows gastric emptying. These effects reduce postprandial glucose excursions and promote satiety through both peripheral and central mechanisms. GIP receptor activation works synergistically with GLP-1 signaling to potentiate insulin secretion and improve beta-cell function. GIP agonism also appears to enhance the tolerability of the compound by counteracting some of the nausea associated with GLP-1 receptor activation alone. The glucagon receptor agonist component differentiates retatrutide from dual agonists. Glucagon activation increases hepatic energy expenditure, promotes lipolysis, and enhances thermogenesis. This drives additional caloric expenditure and preferentially targets hepatic and visceral fat stores, contributing to the superior weight loss observed in clinical trials.
Legal Status
Investigational and not FDA-approved. Lilly has reported five positive Phase 3 studies and plans a biologics license application in the first quarter of 2027. Retatrutide has no approved retail or compounded version; products sold outside authorized trials are unapproved.
Primary Sources
- Retatrutide once weekly for treatment of obesity: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet, 2023.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. New England Journal of Medicine, 2024.
- Efficacy and safety of retatrutide in type 2 diabetes: a phase 2 trial. Diabetes Care, 2023.
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab, 2026.
- Lilly triple agonist retatrutide successful in two additional Phase 3 trials. Lilly Investor Relations, 2026.
Quick Answers
Where is the strongest evidence for Retatrutide?
Retatrutide has the largest sponsor-reported Phase 3 weight-loss signal in the database and now has positive results across five Phase 3 studies. It remains unapproved, and the new results are not yet fully peer reviewed, so tirzepatide remains the evidence-backed approved choice while retatrutide is the leading late-stage candidate. Evidence context: Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease.
What are the main side effects of Retatrutide?
Retatrutide side effects and warning signals include Nausea, Diarrhea, Vomiting, Decreased appetite, and Constipation.
What evidence level is Retatrutide?
Retatrutide is rated Level B; the listed research status is Phase 3.